anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Annulus fibrosus (AF) defect is an important cause of disc re-herniation after discectomy. The self-regeneration ability of the AF is limited, and AF repair is always hindered by the inflammatory microenvironment after injury. Hydrogels represent one of the most promising materials for AF tissue engineering strategies. However, currently available commercial hydrogels cannot withstand the harsh mechanical load within intervertebral disc. In the present study, an innovative triple cross-linked oxidized hyaluronic acid (OHA)-dopamine (DA)- polyacrylamide (PAM) composite hydrogel, modified with collagen mimetic peptide (CMP) and supplied with transforming growth factor beta 1 (TGF-β1) (OHA-DA-PAM/CMP/TGF-β1 hydrogel) was developed for AF regeneration. The hydrogel exhibited robust mechanical strength, strong bioadhesion, and significant self-healing capabilities. Modified with collagen mimetic peptide, the hydrogel exhibited extracellular-matrix-mimicking properties and sustained the AF cell phenotype. The sustained release of TGF-β1 from the hydrogel was pivotal in recruiting AF cells and promoting extracellular matrix production. Furthermore, the composite hydrogel attenuated LPS-induced inflammatory response and promote ECM synthesis in AF cells via suppressing NFκB/NLRP3 pathway. In vivo, the composite hydrogel successfully sealed AF defects and alleviated intervertebral disk degeneration in a rat tail AF defect model. Histological evaluation showed that the hydrogel integrated well with host tissue and facilitated AF repair. The strategy of recruiting endogenous cells and providing an extracellular-matrix-mimicking and anti-inflammatory microenvironment using the mechanically tough composite OHA-DA-PAM/CMP/TGF-β1 hydrogel may be applicable for AF defect repair in the clinic. STATEMENT OF SIGNIFICANCE: Annulus fibrosus (AF) repair is challenging due to its limited self-regenerative capacity and post-injury inflammation. In this study, a mechanically tough and highly bioadhesive triple cross-linked composite hydrogel, modified with collagen mimetic peptide (CMP) and supplemented with transforming growth factor beta 1 (TGF-β1), was developed to facilitate AF regeneration. The sustained release of TGF-β1 enhanced AF cell recruitment, while both TGF-β1 and CMP could modulate the microenvironment to promote AF cell proliferation and ECM synthesis. In vivo, this composite hydrogel effectively promoted the AF repair and mitigated the intervertebral disc degeneration. This research indicates the clinical potential of the OHA-DA-PAM/CMP/TGF-β1 composite hydrogel for repairing AF defects.
The present invention relates to a Chinese traditional patent medicine for treating diabetic heart disease, which takes more than 10 Chinese herbal medicines of alcohol processed Chinese angelica, salvia miltiorrhiza, yanhusuo, raw nutgrass galingale rhizome etc. as the raw materials. The invention has the effects of activating blood circulation, removing blood stasis, dredging collaterals and stopping pain. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the Chinese traditional patent medicine for treating diabetic heart disease. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
PURPOSE:To obtain a detergent compsn. which is excellent in foaming properties, foam quality, and temp. stability and is mild to the skin and hair by incorporating a choline N-acylglutamate into the compsn. CONSTITUTION:A detergent compsn. contg. a choline N-acylglutamate is provided. Since N-acylglutamates are mild to the skin and hair and hardly irritate a human body, they have been used as the main component of a solid soap, a shampoo, etc., known examples being an alkali metal salt, an alkanolamine salt, a basic amino acid salt, and an ammonium salt. However, the alkali metal salt has problems with depositing an insol. matter at low temp. and hardening; other above-mentioned salts are rather inferior in foaming properties to the alkali salt, discolor during storage, and release odor. On the other hand, using a choline as a counter ion of N-acylglutamate gives a detergent compsn. which is excellent in foaming properties, foam quality, and temp. stability and is mild to the skin and hair.
The invention belongs to the field of medicines, relates to a breakthrough that isoliquiritigenin exerts an anti-inflammation effect through inhibiting IFN-gamma induced CXCL10 synthesis, and particularly relates to an application of the isoliquiritigenin in preparation of anti-inflammation medicines in prevention and treatment of hepatitis disease through inhibiting CXCL10 expression. The application relates to an application of the isoliquiritigenin shown as a formula (I) in preparation of medicines for preventing and treating liver inflammation. The medicines are medicines with anti-inflammation effects. The application that the isoliquiritigenin exerts an anti-inflammation effect in the liver inflammation is provided. On the basis of building a hepatitis model, the in-vitro anti-inflammation effect of the isoliquiritigenin is verified by MTT, ELISA, qRT-PCR, and other experiment methods. Results show that the isoliquiritigenin can inhibit the CXCL10 expression and can be used for preparing anti-inflammation preparations for hepatitis, and show that the anti-inflammation effect of the isoliquiritigenin can be used for a part of hepatitis patients in clinic.
Objective:This study analyzed the pure tone audiometry results of the affected ear and the contralateral ear of unilateral Meniere's disease to investigate the correlation of the hearing threshold of the contralateral ear and the hearing prognosis of unilateral Meniere's disease. Methods:In this study, the follow-up data of 135 patients with unilateral Meniere's disease in Beijing Tongren Hospital were used to analyze the pure tone audiometry results of the affected and contralateral ears at the first visit and 1 year later. Results:①At the first visit, there was no statistically significant difference between the mean hearing thresholds of the affected ear in the normal hearing group and the high-frequency hearing loss group of the contralateral ear(P>0.05). ②The range of improvement of hearing thresholds in the affected ear was greater in the contralateral ear normal hearing group than in the contralateral ear high-frequency hearing loss group. In the normal hearing group of the contralateral ear, the hearing thresholds of the affected ear at 0.25 kHz(P<0.01), 0.50 kHz(P<0.01), 1.00 kHz(P<0.01), and 2.00 kHz(P<0.05) were significantly improved; and in the high-frequency hearing loss group of the contralateral ear, the hearing thresholds at 0.25 kHz(P<0.01) hearing thresholds improved significantly, and there was no significant difference between the rest of the frequencies before and after treatment(P>0.05). A consistent pattern was observed in both higher and lower age groups. ③After 1 year of follow-up, the low and mid-frequency hearing of the affected ear improved. 0.25 kHz(P<0.01), 0.50 kHz(P<0.01), 1.00 kHz(P<0.01) hearing thresholds improved significantly; 8.00 kHz hearing thresholds decreased slightly(P<0.05). Conclusion:After standardized treatment, the results of 1-year follow-up suggested that the low-frequency hearing of MD patients could be improved, but the high-frequency hearing was slightly decreased. The hearing prognosis of the affected ear with normal hearing threshold of the contralateral ear may be better.
<P>PROBLEM TO BE SOLVED: To provide a health control system allowing medical inquiry in proper timing according to a category.  <P>SOLUTION: This health control system 10 includes a control server 14, and a user such as a diabetic accesses the control server 14 from a user terminal 12 such as a personal computer via the Internet 22. The control server 14 exhibits a medical inquiry check list of four categories of feeling, motivation, depression and stress to the user terminal 12 in response to the access. The user executes answer input to the medical inquiry according to an execution procedure to the check list. The control server processes the answer input, and stores a processed result thereof in a database 24. Accordingly, the user accesses the database to know estimation (a medical inquiry result) decided by the control server. The control server executes the medical inquiry in a timing believed to be proper according to priority order of each the category to avoid exhibition of the medical inquiry list of all the categories on the same day. Because each the medical inquiry can be executed in the proper execution timing according to the category of the medical inquiry, a burden on the user is reduced.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
The active ingredient of BARHEMSYS is amisulpride, a dopamine-2 (D2) receptor antagonist. Its chemical name is 4-Amino-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-(ethylsulfonyl)-o-anisamide. It has the following chemical structure:

The empirical formula is C17H27N3O4S representing a molecular weight of 369.48.

Amisulpride is a white or almost white crystalline powder. It is practically insoluble in water, sparingly soluble in ethanol and freely soluble in methylene chloride, and has a melting point of around 126°C. The compound is racemic and shows no optical rotation and is not hygroscopic. No other polymorphs of amisulpride have been reported.

BARHEMSYS (amisulpride) injection is a clear, colorless, nonpyrogenic, sterile solution formulation of amisulpride 5 mg/2 mL (2.5 mg/mL) or 10 mg/4 mL (2.5 mg/mL) for intravenous infusion presented in a single-dose vial. It has a pH of approximately 5.0 and the osmolality of the product is between 250 and 330 mOsmol/kg.

Each 2 mL vial of BARHEMSYS contains 5 mg of amisulpride; 18.7 mg of citric acid monohydrate USP; 3.6 mg of sodium chloride USP; 32.64 mg of trisodium citrate dihydrate; hydrochloric acid NF and sodium hydroxide NF as needed to adjust the pH (4.75 to 5.25); and Water for Injection USP to make up to volume.

Each 4 mL vial of BARHEMSYS contains 10 mg of amisulpride; 37.4 mg of citric acid monohydrate USP; 7.2 mg of sodium chloride USP; 65.3 mg of trisodium citrate dihydrate; hydrochloric acid NF and sodium hydroxide NF as needed to adjust the pH (4.75 to 5.25); and Water for Injection USP to make up to volume.
Therapy should be individualized according to the patient’s response to gain maximal therapeutic response and to determine the minimal dose needed to maintain the therapeutic response.

Adults \-- The usual initial dose of LASIX for hypertension is 80mg, usually divided into 40mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.

Changes in blood pressure must be carefully monitored when LASIX is used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50% when LASIX is added to the regimen. As the blood pressure falls under the potentiating effect of LASIX, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.

Geriatric patients \-- In general, dose selection and dose adjustment for the elderly patient should be cautious, usually starting at the low end of the dosing range (see PRECAUTIONS: Geriatric Use).
FIELD: medicine, vascular neurosurgery. SUBSTANCE: the method deals with conducting intravascular operations at aneurysms and carotid- cavernous anastomoses and carrying out the control for patients in postoperational period. One should perform the occlusion with detachable silicone-filled balloon. Moreover, silicone should be contrasted with finely divided bismuth oxide, that is, 2 ml silicone compound should be supplemented with 1 g bismuth oxide. The method enables to decrease the number of complications. EFFECT: higher efficiency of therapy.
Meditation intervention applied during Phase 1 of the study. During Phase 2, the formal meditation intervention is not completed, but participants are followed for outcome measurement. Participants may continue to use meditation in their daily routines or return to their usual routines.
NEW MATERIAL:The azulene derivative of formula I (R<1> is H, 1-10C alkyl or alkenyl, hydroxycarbonyl or alkoxycarbonyl; R<2> and R<3> are H, or 1-10C alkyl or alkenyl). EXAMPLE:Methyl 3-acetyl-7-isopropylazulene-1-carboxylate. USE:Useful especially as an antitumor agent. It has the activity to suppress the growth of cancer cells and is useful in the pharmaceutical industry. It is applied in the form of tablet, capsule, etc. for oral administration, or aseptic solution, etc. for parenteral administration, at a dose of 0.2-500mg per head. PREPARATION:The compound of formula I can be prepared by oxidizing the 3-side chain of the compound of formula II with an oxidizing agent such as 2,3-dichloro-5,6-dicyanobenzoquinone.
Participants in this arm will receive an initial dose of 5 mg. Further titrations will be decided based on clinical response and tolerability (maximum dose of 20 mg). The medication will be taken by mouth in pill form, once daily.
This was a single site, single dose, open-label study with one group of male or female patients between 18-80 years old with a diagnosis of Probable or Definite Amyotrophic Lateral Sclerosis (ALS) according to revised El-Escorial Criteria. Patients seen in the ALS Clinic at the University of Florida were screened to determine eligibility for participation in the study according to the specified inclusion/exclusion criteria. Following informed consent and enrollment, subjects were given a complete physical and neurological examination including the validated Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). Swallowing safety was assessed using the gold standard Videofluoroscopic Swallowing Study (VFSS) to allow direct visualization of the swallowing process and any episodes of penetration or aspiration were quantified using the validated Penetration Aspiration Scale (PAS). Subjects participated in a standardized protocol that includes 11 bolus stimuli presentations of different liquid and food materials to test swallowing function using a progression of textures and materials. Immediately following this assessment, subjects were given a single dose of ROSF 50 mg, placed on the median lingual sulcus of the dorsum of the tongue (area under the tongue on the midline groove that separates the surface of the tongue into right and left halves). Three minutes after the administration of ROSF, the identical standardized VFSS protocol was re-administered to allow a comparison of swallowing safety (using the PAS scale) pre- versus post-ROSF administration.

The original plan was to enroll 30 patients for a final sample size of 25 completed patients. The protocol stipulated that, depending upon the study enrollment rate, the Sponsor could elect to perform an interim analysis using available data from the subset of subjects who had completed the study at that time. An interim assessment of the data was performed after 8 subjects had completed the study and a ninth patient had been screened and was awaiting VFSS. With agreement from the FDA, the Sponsor decided to terminate the study after 9 completed patients, based on the analysis of the first 8 completed patients showing no evidence of a harmful effect of one dose of ROSF 50 mg on swallowing function.
PURPOSE:To obtain the titled defending agent useful for protecting radiation damage, etc., having defending action on nonspecific oxidative invasion, containing Streptococcus pyogenes subjected to streptolysin S production ability elimination treatment as an active ingredient. CONSTITUTION:The titled agent containing Streptococcus pyogenes subjected to streptolysin S production ability elimination treatment as an active ingredient. When the active ingredient is administered to organisms, metallothionein, metallic protein, is induced. Consequently, antioxygenic and organism defending action such as protecting action on radiation damage is produced. L type Streptococcus pyogenes obtained by cultivating a cell of Streptococcus pyogenes under a condition to inhibit a cell wall, e.g. in a isotonic solution containing penicillin, is preferable as the Streptococcus pyogenes.
In this Randomized Controlled Trial the effectiveness of LDN in reducing chronic pain and improvement of quality of life in women with provoked, spontaneous or mixed vulvodynia is assessed on the basis of the test results recommended according to IMMPACT protocol, compared to the placebo arm. Patients remain in the study for 6 months (4 months of treatment with LDN or placebo). There are 5 visits by a gynecologist (diagnosis of vulvodynia, inclusion and exclusion criteria, randomization), nurse, psychologist and physiotherapist: screening, randomization, control telephone visit, final visit and telephone summary visit. Pain perception and quality of life estimation is reported by the patient in e-diary, validated psychology questionnaires are fulfilled and physical examination acc. Fascial Manipulation (CFMS) L. Stecco method is performed. Tolerability of LDN therapy will also be assessed.
Participants randomized to the Health Enhancement Program (HEP) arm will undergo HEP training in groups of 10. HEP will be delivered virtually using the Cisco WebEx platform by trained non-clinician teachers. Participants will be trained for 4 consecutive days (2 hours/day) in the first week, followed by 1-hour weekly reinforcement sessions for 11 weeks. Participants will also be encouraged to practice twice daily at home for 20 minutes per session. They will be given a daily practice log on which they check off a box indicating if they have done their home practice.
Iliopsoas tendonitis, typically caused by impingement with the acetabular cup, occurs in up to 18% of patients after total hip arthroplasty (THA) and up to 30% of patients after hip resurfacing arthroplasty (HRA). We have developed a simulation for detecting iliopsoas impingement and validated it in a previous study of THA patients. However, due to the difference in incidence between HRA and THA, this study had two aims. First, to validate the simulation in a cohort of HRA patients and, second, to comparethe results of the HRA and THA patients to understand any differences in their etiology. We conducted a retrospective search in an experienced surgeon's database for HRA patients with iliopsoas tendonitisand control patients without iliopsoas tendonitis, resulting in two cohorts of 12 patients. Using CT scans, 3D models of the each patient's prosthetic and bony anatomy were generated, landmarked, and simulated. Regarding validation of the simulation for HRA patients, impingement significantly predicted the probability of iliopsoas tendonitis in logistic regression models and the simulation had a sensitivity of 83%, specificity of 100%, and an AUC ROC curve of 0.95. Unexpectedly, the HRA cohort exhibited less impingement than the THA cohort. Our novel simulation has now been demonstrated to detect iliopsoas impingement and differentiate between the symptomatic and asymptomatic cohorts in investigations of THA and HRA patients. This tool has the potential to be used preoperatively, to guide decisions about optimal cup placement, and postoperatively, to assist in the diagnosis of iliopsoas tendonitis.
UCP: family members were invited to present at least one session of the 5 in-hospital intervention session. Parents and infants in the UCP group received 7 after-discharge phone calls (0, 1, 2, 4, 6, 9, and 12 months of corrected age) and neonatal follow-up at 0, 1, 6, 12, 18, and 24 months of corrected age.
INTRODUCTION: Childhood-onset obesity poses significant health risks, including early-onset type 2 diabetes, cardiovascular disease, and reduced quality of life. Hospital-based non-pharmacological obesity care can reduce childhood obesity, but 25% of children do not respond. Therefore, this study investigates the effect of the glucagon-like peptide-1 receptor agonist, semaglutide, as an add-on to hospital-based obesity care in youth who still have obesity following hospital-based obesity care as children. Furthermore, biomedical and psychosocial factors linked to treatment response will be investigated, alongside an exercise-based strategy to prevent weight regain and maintain a healthy body composition after semaglutide treatment.
METHODS AND ANALYSIS: This is an investigator-initiated, randomised, placebo-controlled, double-blind trial. We will enrol expectedly 180-270 young adults aged 18-28 years based on their previous response to a paediatric obesity management programme and their current body mass index (BMI). Participants are categorised into four groups: low treatment response (BMI SD score (SDS) reduction <0.10; BMI ≥30 kg/m2); medium treatment response (BMI SDS reduction >0.25; BMI ≥30 kg/m2); high treatment response (BMI SDS reduction >0.50; BMI <30 kg/m2) and a population-based reference group with normal weight development in childhood. Participants with BMI ≥30 kg/m2 are randomised 2:1 to subcutaneous injections of semaglutide 2.4 mg/week or placebo as an add-on to hospital-based obesity care for 68 weeks. The primary outcome is the change in BMI from randomisation to the end of treatment with semaglutide compared with placebo. Secondary endpoints are changes in weight and body composition.
ETHICS AND DISSEMINATION: The trial has been approved by the Danish Medicines Agency and the Ethical Committee of the Capital Region of Denmark (H-20039422). The trial will be conducted in accordance with the Declaration of Helsinki and follow the guidelines for Good Clinical Practice. Results will be presented at international scientific conferences and published in peer-reviewed scientific journals.
TRIAL REGISTRATION NUMBER: EudraCT 2019-002274-31.
FIELD: medicine, immunology. SUBSTANCE: complex of monoclonal poly-IgA shows specificity with respect to pathogenic microorganisms, allergens or spermatozoons and can be used for protection of mammals from pathogenic microorganisms and as a contraceptive. Complex has a recombinant stabilizing protein. This protein has a region I and at least two regions IV and V of poly-IgA-receptor and does not contain region VI of poly-IgA-receptor. Region I is located at distance about 100-500 amino acids from region IV and V. Complex exhibits proteolytic stability as compared with unbound poly-IgA and the presence of immunoprotective and cross-linking properties of poly-IgA. Invention proposes a method of preparing this complex, a method of testing monoclonal poly-IgA and a method of mammals protection using this complex. EFFECT: enhanced effectiveness of safety immunization. 10 cl, 19 dwg, 5 ex
Medical devices and methods which relate to interaction with food items, either directly or indirectly, in order to manage the food items is disclosed. A medical device includes a scanner such as a bar code scanner, for receiving information about an item such as food nutritional information. The medical device can be a remote controller for a second medical device. The medical device also includes at least one processor for processing information.  The processor processes scanned information and can also determine acceptability. The processor can also receive input of an estimate of an amount of an item to be ingested by a user, calculate estimated bolus amount of insulin required by a user based upon at least one blood glucose value; and provide information related to said bolus amount and/or acceptability of the item to the user.